Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

Open to males ages 18 years and up

Subjects are eligible to be included in the study only if all the following criteria apply:

• Subjects planned to undergo radical prostatectomy.

• Histologically or cytologically confirmed adenocarcinoma of the prostate at initial biopsy, without neuroendocrine differentiation, signet cell, or small cell features.

  Intermediate- or high-risk localized prostate cancer, defined as:

• Gleason score of 4+3 or higher AND iPSA >10 OR
• Clinically advanced (cT3) on MRI imaging obtained within 3 months prior to screening AND/OR
• Positive locoregional lymph nodes as detected by PSMA-PET scans OR equal or ≤ 5 local lymph nodes on MRI can be enrolled.
• Subjects must have undergone a gallium-68 prostate-specific membrane antigen (68Ga-PSMA-11) or a piflufolastat F 18 PET (CT or MRI) scan within 3 months prior to screening as part of the SOC.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

Subjects are excluded from the study if any of the following criteria apply:

• Prior treatment for subject's prostate cancer.
• Any evidence of metastases outside of the surgical resection field identified by conventional imaging or PSMA-PET scans.
• Confirmed history or current autoimmune disease or other diseases resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy.
• Subject with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment:
• Subject has known active infection requiring antibiotic treatment. Upon completion of antibiotics and resolution of symptoms, the subject may be considered eligible for the study from an infection standpoint.
• History of arterial or venous thrombosis or other diseases requiring permanent anticoagulation (eg, stroke, transient ischemic attack, pulmonary embolism, or deep vein thrombosis):
• Patients requiring anticoagulation due to atrial fibrillation may be allowed if they can safely stop the anticoagulation for the perisurgical timeframe.
• Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association ≥ class II) within 12 months of first dose of xaluritamig with the exception of ischemia or non-ST segment elevation myocardial infarction controlled with stent placement more than 6 months prior to first dose of xaluritamig.
• Requirement for chronic systemic corticosteroid therapy
• Currently receiving treatment in another investigational device or drug study, or less than 4 weeks (since ending treatment on another investigational device or drug study[ies]). Other investigational procedures and participation in observational research studies while participating in this study are excluded with the exception of investigational scans.